Skip to main content

MoneyWorks4Me

Balaxi Pharma. - Quaterly Results

10 Feb 2025 Evaluate
Net sales declined -12.14%  to  Rs. 111.58 million from Rs. 127.00 millions.Net Profit for the quarter ended December 2024 zoomed to 257.17% from Rs. 4.88 millions to Rs. 17.43  millions.Operating profit for the quarter ended December 2024 rose to 30.14 millions as compared to 13.09 millions of corresponding quarter ended December 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 111.58 127.00 -12.14 513.39 542.92 -5.44 701.96 1081.38 -35.09
Other Income 29.17 10.30 183.20 50.53 23.09 118.84 23.99 66.04 -63.67
PBIDT 30.14 13.09 130.25 81.39 72.71 11.94 76.35 234.26 -67.41
Interest 5.66 4.11 37.71 13.69 10.31 32.78 15.41 4.59 235.73
PBDT 24.48 8.98 172.61 67.70 62.40 8.49 60.94 229.67 -73.47
Depreciation 1.14 1.32 -13.64 3.45 3.95 -12.66 5.11 5.15 -0.78
PBT 23.34 7.66 204.70 64.25 58.45 9.92 55.83 224.52 -75.13
TAX 5.91 2.78 112.59 16.45 16.21 1.48 19.33 62.29 -68.97
Deferred Tax -0.19 -0.27 -29.63 -0.57 -0.33 72.73 -1.05 10.62 -109.89
PAT 17.43 4.88 257.17 47.80 42.24 13.16 36.50 162.23 -77.50
Equity 110.42 102.30 7.94 110.42 102.30 7.94 108.98 101.81 7.04
PBIDTM(%) 27.01 10.31 162.07 15.85 13.39 18.38 10.88 21.66 -49.79
Peers
Company Name CMP
Redington 349.60
Adani Enterprises 2682.00
Amrapali Industries 32.78
Maxgrow India 174.80
Rashi Peripheral 689.15
View more..